A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Prostate cancer (PCa) is the most commonly diagnosed cancer in American men with a subset inevitably presenting with metastatic disease to the bone. A well-recognized limitation in evaluating new treatments for metastatic PCa is the inability to use imaging to objectively assess response therapy. In this study, we evaluated the feasibility of clinically translating the functional diffusion map (fDM) imaging biomarker for quantifying the spatiotemporal effects of bone tumor response in a patient treated for metastatic PCa with bone metastases. A patient beginning therapy was scanned using MRI before treatment and again at 2 and 8 weeks post-treatment initiation to quantify changes in tumor diffusion values. Three metastatic lesions were identified for fDM analysis, all of which all demonstrated an early increase in diffusion values at 2 weeks, which increased further at 8 weeks post-treatment initiation. This finding correlated with a decrease in the patient's prostate-specific antigen (PSA) levels suggestive of patient response. CT, bone scans, and anatomic MRI images obtained posttreatment were found to be uninformative for the assessment of treatment effectiveness. This study presents the feasibility of fDM-measurements in osseous lesions over time and shows that changes in fDM values were consistent with therapeutic response. Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer.
Lee
Kuei C
KC
Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.
Bradley
Deborah A
DA
Hussain
Maha
M
Meyer
Charles R
CR
Chenevert
Thomas L
TL
Jacobson
Jon A
JA
Johnson
Timothy D
TD
Galban
Craig J
CJ
Rehemtulla
Alnawaz
A
Pienta
Kenneth J
KJ
Ross
Brian D
BD
D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary*; D000368:Aged; D000813:Anilides / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001834:Body Water / Q000378:metabolism; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary*; D002463:Cell Membrane Permeability; D038524:Diffusion Magnetic Resonance Imaging; D005240:Feasibility Studies; D017273:Goserelin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009570:Nitriles / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D011877:Radionuclide Imaging; D014057:Tomography, X-Ray Computed; D014105:Tosyl Compounds / Q000008:administration & dosage; D016896:Treatment Outcome; D051598:Whole Body Imaging
D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D017273:Goserelin; C053541:bicalutamide; D017430:Prostate-Specific Antigen